Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Expects Sharp Drop In Drug Applications This Year

This article was originally published in The Pink Sheet Daily

Executive Summary

Announcing the PDUFA fees for fiscal 2011, agency says it expects to receive 117.5 fee-paying full application equivalents in the current fiscal year, down 16 percent from the 2009 level.

You may also be interested in...



FDA Sees Another Submission Decrease In FY 2011, Increases Application Fees

The figures continue a recent trend of decreases in fee-paying full application equivalents but were not as low as had been estimated.

FDA Sees Another Submission Decrease In FY 2011, Increases Application Fees

The figures continue a recent trend of decreases in fee-paying full application equivalents but were not as low as had been estimated.

NDA, BLA Submissions Expected To Fall Again in FY 2011

FDA estimates that the number of fee-paying applications will continue to decline, meaning the user fee itself will increase more than 19% to $1.842 million for applications requiring clinical data.

Related Content

Topics

UsernamePublicRestriction

Register

GB140150

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel